HCA
BMRN icon

Heck Capital Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Heck Capital Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2
Closed -$131 – 309
2024
Q4 		$131 Buy
+2
New +$134 ﹤0.01% 794

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Heck Capital Advisors's BMRN Position: Q1 2025 in Review

Heck Capital Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2025, closing a stake of 2 shares — an estimated $131 sold.

Heck Capital Advisors first reported a position in BMRN in Q4 2024 and held it in 1 quarter. The position peaked at $131 in Q4 2024. 585 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

  • Heck Capital Advisors reported no remaining BioMarin Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Heck Capital Advisors sold 2 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $131.
  • Heck Capital Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Heck Capital Advisors's BioMarin Pharmaceuticals position peaked at $131 in Q4 2024.
  • 585 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on Heck Capital Advisors's 13F filing for Q1 2025, filed 13 May 2025.